Sitryx, a new biopharmaceutical company, has launched USD30m fundraising for the development of disease modifying therapeutics in immunometabolism, a fast-emerging area of investigation into the role of metabolic pathways in immune cell function, it was reported yesterday.
The company was founded with seed funding from SV Health investors and raised a total of USD30m from a syndicate of specialist international healthcare investors co-led by SV Health Investors and Sofinnova Partners, and which also included Longwood Fund and the global healthcare company, GSK.
The investment will be utilised to develop disease-modifying therapies in immuno-oncology and immuno-inflammation.
Chemomab secures new patents for CM-101 monoclonal antibody
argenx receives FDA priority review for VYVGART Hytrulo in CIDP
AffaMed Therapeutics' DEXTENZA NDA accepted by Singapore regulator
AbbVie showcases gastroenterology portfolio at ECCO Congress
Japan approves Sanofi's Dupixent for chronic spontaneous urticaria
Ono partners with Shattuck Labs for bifunctional fusion proteins
Zymedi commences first in human dosage of ZMA001
Bio-Thera Solutions commences dosing in BAT6026 Phase IA/IIB clinical trial
EicOsis Human Health commences EC5026 Phase 1b multiple-ascending dose clinical trial
Takeda's HyQvia approved for maintenance therapy in CIDP patients
Celltrion USA submits CT-P47 Biologics License Application to FDA
Formosa Pharmaceuticals agrees licensing deal in Brazil for APP13007